F. Masuhr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
F. Masuhr has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Markus Alexander Busch
Department of Epidemiology and Health Monitoring, Robert Koch Institute, General-Pape-Strasse 62-66, 12101 Berlin, Germany
5 shared publications K. Einhäupl
Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
4 shared publicationsK M Einhäupl
Neurologische Klinik und Poliklinik, Humboldt-Universität, Berlin
2 shared publicationsS. Mehraein
Department of Psychiatry, University of Freiburg, Freiburg, Germany
2 shared publicationsB. Vetter
Dept. of Pediatrics, Charité University Hospital, Berlin, Germany
1 shared publicationC Zimmer
1 shared publication
Latest Publications
- 14 June 2016
- Published by Wiley in European Journal of Neurology
- Vol. 23 (9) , 1387-1392
Outcome of heparin‐treated patients with acute cerebral venous sinus thrombosis: influence of the temporal pattern of intracerebral haemorrhage
Background and purpose: The influence of temporal patterns of intracerebral haemorrhage (ICH) on the outcome of heparin‐treated patients with cerebral venous sinus thrombosis (CVST) has not been examined systematically.Methods: Temporal patterns of ICH and their influence on survival without disability (modified Rankin Scale score ≤1 point) at hospital discharge were examined in 141 consecutive hospital‐admitted patients with acute CVST who were treated with intravenous unfractionated heparin.Results: Of all 141 patients (median age 40 years; 73% women), 59 (42%) had ICH at the time of diagnosis (early ICH). Of these, seven (12%) subsequently had extension of ICH and 13 (22%) had additional ICHs at other locations (delayed ICH). Of 82 patients without early ICH, nine (11%) later had delayed ICH. After a median hospital stay of 26 days, 107 patients (76%) were discharged without disability. Patients with early ICH were less likely to survive without disability until discharge than those without early ICH [63% vs. 85%; risk ratio (RR) 0.73; P = 0.005]. The association was attenuated after adjusting for age, sex and impaired consciousness on admission (RR 0.83; P = 0.03). Taking temporal patterns of ICH into account, early ICH with subsequent complication (extension or delayed ICH) had a larger influence on survival without disability (RR 0.57; 95% confidence interval 0.35–0.95) than early ICH without complications (RR 0.78; 95% confidence interval 0.67–0.91).Conclusions: Heparin‐treated CVST patients were less likely to survive without disability when ICH was present on admission. This association may largely be driven by subsequent extension of haemorrhage or additionally occurring delayed haemorrhage.
- 14 June 2016
- Published by Wiley in European Journal of Neurology
- Vol. 23 (9) , 1387-1392
Outcome of heparin‐treated patients with acute cerebral venous sinus thrombosis: influence of the temporal pattern of intracerebral haemorrhage
Background and purpose: The influence of temporal patterns of intracerebral haemorrhage (ICH) on the outcome of heparin‐treated patients with cerebral venous sinus thrombosis (CVST) has not been examined systematically.Methods: Temporal patterns of ICH and their influence on survival without disability (modified Rankin Scale score ≤1 point) at hospital discharge were examined in 141 consecutive hospital‐admitted patients with acute CVST who were treated with intravenous unfractionated heparin.Results: Of all 141 patients (median age 40 years; 73% women), 59 (42%) had ICH at the time of diagnosis (early ICH). Of these, seven (12%) subsequently had extension of ICH and 13 (22%) had additional ICHs at other locations (delayed ICH). Of 82 patients without early ICH, nine (11%) later had delayed ICH. After a median hospital stay of 26 days, 107 patients (76%) were discharged without disability. Patients with early ICH were less likely to survive without disability until discharge than those without early ICH [63% vs. 85%; risk ratio (RR) 0.73; P = 0.005]. The association was attenuated after adjusting for age, sex and impaired consciousness on admission (RR 0.83; P = 0.03). Taking temporal patterns of ICH into account, early ICH with subsequent complication (extension or delayed ICH) had a larger influence on survival without disability (RR 0.57; 95% confidence interval 0.35–0.95) than early ICH without complications (RR 0.78; 95% confidence interval 0.67–0.91).Conclusions: Heparin‐treated CVST patients were less likely to survive without disability when ICH was present on admission. This association may largely be driven by subsequent extension of haemorrhage or additionally occurring delayed haemorrhage.
- 1 November 2012
- Published by Springer Nature in Die Innere Medizin
- Vol. 53 (12) , 1496-1504
Primär- und Sekundärprävention des Schlaganfalls
Eine effektive Prävention bleibt trotz beachtlicher Fortschritte in der Akuttherapie die aussichtsreichste Methode zur Senkung der Krankheitslast durch einen Schlaganfall. Ein gesunder Lebensstil und die Behandlung kardiometabolischer Risikofaktoren sind dabei die Eckpfeiler der Primär- und Sekundärprävention. In der Primärprävention sind Thrombozytenfunktionshemmer aufgrund des höheren Blutungsrisikos nicht indiziert. In der Sekundärprävention des ischämischen Schlaganfalls sind sie jedoch wirksam, wobei die konsistentesten Daten für Acetylsalicylsäure und Clopidogrel vorliegen. Neue orale Antikoagulanzien haben gegenüber Vitamin-K-Antagonisten eine geringfügig bessere Wirksamkeit und reduzieren das Risiko intrakranieller Blutungen. Sie bieten die Möglichkeit, Risikopatienten mit Vorhofflimmern, die bislang nicht mit Vitamin-K-Antagonisten behandelt werden konnten, adäquat zu behandeln. Bei symptomfreien Patienten mit Karotisstenose ist der Nutzen einer Operation marginal. Sie sollte vor dem Hintergrund einer optimierten medikamentösen Therapie kritisch betrachtet werden. Für Patienten mit symptomatischen Stenosen ist die Operation der Stentangioplastie aufgrund geringerer periprozeduraler Komplikationen überlegen. Patienten mit symptomatischen intrakraniellen Stenosen oder kryptogenen Schlaganfällen bei persistierendem Foramen ovale sollten medikamentös behandelt werden. Despite considerable advances in acute stroke therapy, stroke prevention remains the most promising approach for reducing the burden of stroke. A healthy lifestyle and the treatment of cardiometabolic risk factors are the cornerstones of both primary and secondary stroke prevention. Due to a proportionately higher risk of bleeding complications, platelet inhibitors are not recommended for primary stroke prevention. Platelet inhibitors are effective in the secondary prevention of stroke with acetyl salicylic acid (ASS) and clopidogrel showing the most consistent data. New oral anticoagulants are slightly more effective than coumarin and significantly reduce the risk of intracranial hemorrhage. They offer the opportunity to bring more patients with atrial fibrillation at risk for stroke into anticoagulation particularly those on ASS therapy. Surgery for patients with asymptomatic carotid artery stenosis should be viewed critically with respect to an only marginal benefit and improvement in medical therapies. Carotid endarterectomy remains the gold standard for patients with symptomatic carotid stenosis because of an increased procedural stroke risk with carotid stenting. Patients with symptomatic intracranial stenosis or cryptogenic stroke and a patent foramen ovale should receive only medical treatment.
- 1 November 2012
- Published by Springer Nature in Die Innere Medizin
- Vol. 53 (12) , 1496-1504
Primär- und Sekundärprävention des Schlaganfalls
Eine effektive Prävention bleibt trotz beachtlicher Fortschritte in der Akuttherapie die aussichtsreichste Methode zur Senkung der Krankheitslast durch einen Schlaganfall. Ein gesunder Lebensstil und die Behandlung kardiometabolischer Risikofaktoren sind dabei die Eckpfeiler der Primär- und Sekundärprävention. In der Primärprävention sind Thrombozytenfunktionshemmer aufgrund des höheren Blutungsrisikos nicht indiziert. In der Sekundärprävention des ischämischen Schlaganfalls sind sie jedoch wirksam, wobei die konsistentesten Daten für Acetylsalicylsäure und Clopidogrel vorliegen. Neue orale Antikoagulanzien haben gegenüber Vitamin-K-Antagonisten eine geringfügig bessere Wirksamkeit und reduzieren das Risiko intrakranieller Blutungen. Sie bieten die Möglichkeit, Risikopatienten mit Vorhofflimmern, die bislang nicht mit Vitamin-K-Antagonisten behandelt werden konnten, adäquat zu behandeln. Bei symptomfreien Patienten mit Karotisstenose ist der Nutzen einer Operation marginal. Sie sollte vor dem Hintergrund einer optimierten medikamentösen Therapie kritisch betrachtet werden. Für Patienten mit symptomatischen Stenosen ist die Operation der Stentangioplastie aufgrund geringerer periprozeduraler Komplikationen überlegen. Patienten mit symptomatischen intrakraniellen Stenosen oder kryptogenen Schlaganfällen bei persistierendem Foramen ovale sollten medikamentös behandelt werden. Despite considerable advances in acute stroke therapy, stroke prevention remains the most promising approach for reducing the burden of stroke. A healthy lifestyle and the treatment of cardiometabolic risk factors are the cornerstones of both primary and secondary stroke prevention. Due to a proportionately higher risk of bleeding complications, platelet inhibitors are not recommended for primary stroke prevention. Platelet inhibitors are effective in the secondary prevention of stroke with acetyl salicylic acid (ASS) and clopidogrel showing the most consistent data. New oral anticoagulants are slightly more effective than coumarin and significantly reduce the risk of intracranial hemorrhage. They offer the opportunity to bring more patients with atrial fibrillation at risk for stroke into anticoagulation particularly those on ASS therapy. Surgery for patients with asymptomatic carotid artery stenosis should be viewed critically with respect to an only marginal benefit and improvement in medical therapies. Carotid endarterectomy remains the gold standard for patients with symptomatic carotid stenosis because of an increased procedural stroke risk with carotid stenting. Patients with symptomatic intracranial stenosis or cryptogenic stroke and a patent foramen ovale should receive only medical treatment.
- Top Cited Papers
- 13 September 2010
- Published by Wiley in European Journal of Neurology
- Vol. 17 (10) , 1229-1235
EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients
Background: Cerebral venous and sinus thrombosis (CVST) is a rather rare disease which accounts for Methods: We searched MEDLINE (National Library of Medicine), the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane Library to review the strength of evidence to support these interventions and the preparation of recommendations on the therapy of CVST based on the best available evidence. Review articles and book chapters were also included. Recommendations were reached by consensus. Where there was a lack of evidence but consensus was clear we stated our opinion as good practice points.Results and conclusions: Patients with CVST without contraindications for anticoagulation (AC) should be treated either with body weight‐adjusted subcutaneous LMWH or with dose‐adjusted intravenous heparin (level B recommendation). Concomitant intracranial haemorrhage (ICH) related to CVST is not a contraindication for heparin therapy. The optimal duration of oral anticoagulant therapy after the acute phase is unclear. Oral AC may be given for 3 months if CVST was secondary to a transient risk factor, for 6–12 months in patients with idiopathic CVST and in those with “mild” thrombophilia, such as heterozygous factor V Leiden or prothrombin G20210A mutation and high plasma levels of factor VIII. Indefinite AC should be considered in patients with recurrent episodes of CVST and in those with one episode of CVST and ‘severe’ thrombophilia, such as antithrombin, protein C or protein S deficiency, homozygous factor V Leiden or prothrombin G20210A mutation, antiphospholipid antibodies and combined abnormalities (good practice point). There is insufficient evidence to support the use of either systemic or local thrombolysis in patients with CVST. If patients deteriorate despite adequate AC and other causes of deterioration have been ruled out, thrombolysis may be a therapeutic option in selected cases, possibly in those without large ICH and threatening herniation (good practice point). There are no controlled data about the risks and benefits of certain therapeutic measures to reduce an elevated intracranial pressure (with brain displacement) in patients with severe CVST. However, in severe cases with impending herniation craniectomy can be used as a life‐saving intervention (good practice point).
- 13 September 2010
- Published by Wiley in European Journal of Neurology
- Vol. 17 (10) , 1229-1235
Top Cited PapersEFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients
Background: Cerebral venous and sinus thrombosis (CVST) is a rather rare disease which accounts for Methods: We searched MEDLINE (National Library of Medicine), the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane Library to review the strength of evidence to support these interventions and the preparation of recommendations on the therapy of CVST based on the best available evidence. Review articles and book chapters were also included. Recommendations were reached by consensus. Where there was a lack of evidence but consensus was clear we stated our opinion as good practice points.Results and conclusions: Patients with CVST without contraindications for anticoagulation (AC) should be treated either with body weight‐adjusted subcutaneous LMWH or with dose‐adjusted intravenous heparin (level B recommendation). Concomitant intracranial haemorrhage (ICH) related to CVST is not a contraindication for heparin therapy. The optimal duration of oral anticoagulant therapy after the acute phase is unclear. Oral AC may be given for 3 months if CVST was secondary to a transient risk factor, for 6–12 months in patients with idiopathic CVST and in those with “mild” thrombophilia, such as heterozygous factor V Leiden or prothrombin G20210A mutation and high plasma levels of factor VIII. Indefinite AC should be considered in patients with recurrent episodes of CVST and in those with one episode of CVST and ‘severe’ thrombophilia, such as antithrombin, protein C or protein S deficiency, homozygous factor V Leiden or prothrombin G20210A mutation, antiphospholipid antibodies and combined abnormalities (good practice point). There is insufficient evidence to support the use of either systemic or local thrombolysis in patients with CVST. If patients deteriorate despite adequate AC and other causes of deterioration have been ruled out, thrombolysis may be a therapeutic option in selected cases, possibly in those without large ICH and threatening herniation (good practice point). There are no controlled data about the risks and benefits of certain therapeutic measures to reduce an elevated intracranial pressure (with brain displacement) in patients with severe CVST. However, in severe cases with impending herniation craniectomy can be used as a life‐saving intervention (good practice point).
- 23 January 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (2) , 139-143
Comparative evaluation of 2D time‐of‐flight and 3D elliptic centric contrast‐enhanced MR venography in patients with presumptive cerebral venous and sinus thrombosis
We retrospectively evaluated an elliptic centric ordered 3D (ec 3D) magnetic resonance venography (MRV) technique in comparison to 2D time‐of‐flight (2D TOF) MRV in patients with presumptive cerebral venous sinus thrombosis (CVST). Twenty‐five patients (mean age 40.6 ± 16.5 years) with presumptive CVST underwent cerebral MRI including 2D TOF and ec 3D MRV. Radiologic findings and clinical outcome were correlated. MRV studies were evaluated by two neuroradiologists in a blinded manner for image quality, assessment of various sinus, internal cerebral veins (ICV), vein of Labbé and Galen (VL/VG) as well as for additional imaging procedures required. Sensitivity/specificity of ec 3D MRV amounted to 85.7%/97.2% as compared with 2D TOF 71.4%/55.6 %. Ec 3D MRV performed superior in terms of image quality as well as assessment of all sinus and veins except for the straight sinus. Additional imaging procedures were less often required in ec 3D MRV studies (28% vs. 66% for 2D TOF MRV; P < 0.001). Interobserver agreement was significantly increased by using ec 3D MRV (93.1% vs. 70.9% of readings). The results of our study provide additional evidence for the superiority of ec 3D compared with 2D TOF MR venography for the diagnosis or exclusion of acute CVST in daily clinical practice.
- 23 January 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (2) , 139-143
Comparative evaluation of 2D time‐of‐flight and 3D elliptic centric contrast‐enhanced MR venography in patients with presumptive cerebral venous and sinus thrombosis
We retrospectively evaluated an elliptic centric ordered 3D (ec 3D) magnetic resonance venography (MRV) technique in comparison to 2D time‐of‐flight (2D TOF) MRV in patients with presumptive cerebral venous sinus thrombosis (CVST). Twenty‐five patients (mean age 40.6 ± 16.5 years) with presumptive CVST underwent cerebral MRI including 2D TOF and ec 3D MRV. Radiologic findings and clinical outcome were correlated. MRV studies were evaluated by two neuroradiologists in a blinded manner for image quality, assessment of various sinus, internal cerebral veins (ICV), vein of Labbé and Galen (VL/VG) as well as for additional imaging procedures required. Sensitivity/specificity of ec 3D MRV amounted to 85.7%/97.2% as compared with 2D TOF 71.4%/55.6 %. Ec 3D MRV performed superior in terms of image quality as well as assessment of all sinus and veins except for the straight sinus. Additional imaging procedures were less often required in ec 3D MRV studies (28% vs. 66% for 2D TOF MRV; P < 0.001). Interobserver agreement was significantly increased by using ec 3D MRV (93.1% vs. 70.9% of readings). The results of our study provide additional evidence for the superiority of ec 3D compared with 2D TOF MR venography for the diagnosis or exclusion of acute CVST in daily clinical practice.
- 20 July 2006
- Published by Wiley in European Journal of Neurology
- Vol. 13 (8) , 852-856
Risk and predictors of early epileptic seizures in acute cerebral venous and sinus thrombosis
We assessed the risk and determined predictors of early epileptic seizures (ES) in patients with acute cerebral venous and sinus thrombosis (CVST). A prospective series of 194 consecutive patients with acute CVST admitted to neurological wards in two German university hospitals was analysed for frequency of ES and in‐hospital mortality. Demographic, clinical and radiological characteristics during the acute stage were retrospectively analysed for significant association with ES in univariate and multivariate analyses. During the acute stage, 19 patients (9.8%) died. Early symptomatic seizures were found in 86 patients (44.3%). Status epilepticus occurred in 11 patients (12.8%) of whom four died. Amongst patients with epileptic seizures, mortality was three times higher in those with status than in those without (36.4% and 12%, respectively). In multivariate logistic regression analysis, motor deficit [odds ratio (OR) 5.8; 95% CI 2.98–11.42; P < 0.001], intracranial haemorrhage (OR 2.8; 95% CI 1.46–5.56; P = 0.002) and cortical vein thrombosis (OR 2.9; 95% CI 1.43–5.96; P = 0.003) were independent predictors of early epileptic seizures. Status epilepticus was an important source of morbidity and early mortality in patients with CVST in this study. Patients with focal motor deficits, cortical vein thrombosis and intracranial haemorrhage carried the highest risk for ES. Prophylactic antiepileptic treatment may be an option for these patients.
- 20 July 2006
- Published by Wiley in European Journal of Neurology
- Vol. 13 (8) , 852-856
Risk and predictors of early epileptic seizures in acute cerebral venous and sinus thrombosis
We assessed the risk and determined predictors of early epileptic seizures (ES) in patients with acute cerebral venous and sinus thrombosis (CVST). A prospective series of 194 consecutive patients with acute CVST admitted to neurological wards in two German university hospitals was analysed for frequency of ES and in‐hospital mortality. Demographic, clinical and radiological characteristics during the acute stage were retrospectively analysed for significant association with ES in univariate and multivariate analyses. During the acute stage, 19 patients (9.8%) died. Early symptomatic seizures were found in 86 patients (44.3%). Status epilepticus occurred in 11 patients (12.8%) of whom four died. Amongst patients with epileptic seizures, mortality was three times higher in those with status than in those without (36.4% and 12%, respectively). In multivariate logistic regression analysis, motor deficit [odds ratio (OR) 5.8; 95% CI 2.98–11.42; P < 0.001], intracranial haemorrhage (OR 2.8; 95% CI 1.46–5.56; P = 0.002) and cortical vein thrombosis (OR 2.9; 95% CI 1.43–5.96; P = 0.003) were independent predictors of early epileptic seizures. Status epilepticus was an important source of morbidity and early mortality in patients with CVST in this study. Patients with focal motor deficits, cortical vein thrombosis and intracranial haemorrhage carried the highest risk for ES. Prophylactic antiepileptic treatment may be an option for these patients.
- 1 August 2004
- Published by Wiley in European Journal of Neurology
- Vol. 11 (8) , 555-558
A negative personal and family history for venous thrombotic events is not sufficient to exclude thrombophilia in patients with cerebral venous thrombosis
A hereditary thrombophilia is found in 20-30% of patients with cerebral venous thrombosis (CVT). These patients might have an increased rate of a positive personal or family history of venous thrombotic events. We investigated the diagnostic value of a structured personal and family history for venous thrombotic events in 56 consecutive cases of CVT. Fourteen of 56 patients (25%) had a hereditary thrombophilia, mostly factor V Leiden. Patients with both CVT and hereditary thrombophilia had more frequently a positive family and personal history than patients affected by CVT only but the difference was not strong enough to differ from the 42 CVT patients without thrombophilia (43% vs. 31%; P = 0.52 and 14% vs. 10 %; P = 0.63). We conclude that a negative personal and family history of venous thrombotic events is not sufficient to exclude thrombophilia and patients with CVT should be tested for inherited thrombophilia regardless of the patient's past personal and family history for venous thrombotic events.
- 1 August 2004
- Published by Wiley in European Journal of Neurology
- Vol. 11 (8) , 555-558
A negative personal and family history for venous thrombotic events is not sufficient to exclude thrombophilia in patients with cerebral venous thrombosis
A hereditary thrombophilia is found in 20-30% of patients with cerebral venous thrombosis (CVT). These patients might have an increased rate of a positive personal or family history of venous thrombotic events. We investigated the diagnostic value of a structured personal and family history for venous thrombotic events in 56 consecutive cases of CVT. Fourteen of 56 patients (25%) had a hereditary thrombophilia, mostly factor V Leiden. Patients with both CVT and hereditary thrombophilia had more frequently a positive family and personal history than patients affected by CVT only but the difference was not strong enough to differ from the 42 CVT patients without thrombophilia (43% vs. 31%; P = 0.52 and 14% vs. 10 %; P = 0.63). We conclude that a negative personal and family history of venous thrombotic events is not sufficient to exclude thrombophilia and patients with CVT should be tested for inherited thrombophilia regardless of the patient's past personal and family history for venous thrombotic events.
- 30 April 2004
- Vol. 9 (4) , 199-206
Thromboprophylaxis and early antithrombotic therapy in patients with acute ischemic stroke and cerebral venous and sinus thrombosis.
So far, neither treatment with standard unfractionated heparin (UFH) nor with low-molecular-weight heparin (LMWH) has been shown to reduce mortality or to improve neurological outcome in patients with acute ischemic stroke. Although a reduction of early recurrent stroke has been demonstrated for the use of subcutaneous UFH, this benefit was offset by a similar-sized increase in hemorrhagic stroke. Double-blinded studies of LMWH have demonstrated no difference between active treatment and placebo suggesting that LMWH is not effective for the early secondary prevention of ischemic stroke. Although UFH and LMWH may be beneficial in certain subgroups of stroke who are at high risk for early stroke recurrence, these subgroups are still to be defined. Currently, low-dose UFH and LMWH can only be recommended for prophylaxis of deep vein thrombosis in patients with acute ischemic stroke with impaired mobility or other factors determining a particular high risk of venous thromboembolism. Available treatment data from controlled trials favor the use of anticoagulation as the first-line therapy for patients with cerebral venous and sinus thrombosis because it may reduce the risk of a fatal outcome and severe disability and does not promote intracranial hemorrhage.
- 30 April 2004
- Vol. 9 (4) , 199-206
Thromboprophylaxis and early antithrombotic therapy in patients with acute ischemic stroke and cerebral venous and sinus thrombosis.
So far, neither treatment with standard unfractionated heparin (UFH) nor with low-molecular-weight heparin (LMWH) has been shown to reduce mortality or to improve neurological outcome in patients with acute ischemic stroke. Although a reduction of early recurrent stroke has been demonstrated for the use of subcutaneous UFH, this benefit was offset by a similar-sized increase in hemorrhagic stroke. Double-blinded studies of LMWH have demonstrated no difference between active treatment and placebo suggesting that LMWH is not effective for the early secondary prevention of ischemic stroke. Although UFH and LMWH may be beneficial in certain subgroups of stroke who are at high risk for early stroke recurrence, these subgroups are still to be defined. Currently, low-dose UFH and LMWH can only be recommended for prophylaxis of deep vein thrombosis in patients with acute ischemic stroke with impaired mobility or other factors determining a particular high risk of venous thromboembolism. Available treatment data from controlled trials favor the use of anticoagulation as the first-line therapy for patients with cerebral venous and sinus thrombosis because it may reduce the risk of a fatal outcome and severe disability and does not promote intracranial hemorrhage.
- 1 January 2004
- Published by Springer Nature in Neurocritical Care
- Vol. 1 (3) , 355-362
Cerebral Venous and Sinus Thrombosis: Patients With a Fatal Outcome During Intravenous Dose-Adjusted Heparin Treatment
Introduction:Although anticoagulation (AC) reduces the risk of a fatal outcome or severe disability in patients with cerebral venous and sinus thrombosis (CVST), prognosis of severe cases is still...
- 1 January 2004
- Published by Springer Nature in Neurocritical Care
- Vol. 1 (3) , 355-362
Cerebral Venous and Sinus Thrombosis: Patients With a Fatal Outcome During Intravenous Dose-Adjusted Heparin Treatment
Introduction:Although anticoagulation (AC) reduces the risk of a fatal outcome or severe disability in patients with cerebral venous and sinus thrombosis (CVST), prognosis of severe cases is still...
- 3 July 2002
- Published by Wiley in European Journal of Neurology
- Vol. 9 (4) , 430-432
Relapsing myelitis with pathological visual evoked potentials: a case of neuromyelitis optica?
- 3 July 2002
- Published by Wiley in European Journal of Neurology
- Vol. 9 (4) , 430-432
Relapsing myelitis with pathological visual evoked potentials: a case of neuromyelitis optica?